DOCSLIB.ORG

1445062001 Pectylin-C Expectorant Ipca Laboratories Ltd. India Freely 1446062001T Metrogyl V-Gel with Unique Pharmaceutical India Third Schedule Applicator Labs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1445062001 Pectylin-C Expectorant Ipca Laboratories Ltd. India Freely 1446062001T Metrogyl V-Gel with Unique Pharmaceutical India Third Schedule Applicator Labs List of Drugs Registered in Accordance with the provisions of the Food and Drugs Act and Regulations Chapter 30:01 Year 2001 DAN TRADE NAME AND MANUFACTURER COUNTRY CONDITION FORM OF ORIGIN OF SALE 1445062001 Pectylin-C Expectorant Ipca Laboratories Ltd. India Freely 1446062001T Metrogyl V-Gel with Unique Pharmaceutical India Third Schedule Applicator Labs. (A Division of J.B. Chemicals & Pharmaceuticals Ltd.) 1447062001T Nicardia CD Retard 30 Unique Pharmaceutical India Third Schedule Tablets Labs. (A Division of J.B. Chemicals & Pharmaceuticals Ltd.) 1448062001T Lisnop-10 Tablets Ajanta Pharma Limited India Third Schedule 1449062001T Candizole Cream Bal Pharma Ltd. India Third Schedule 1450062001T Ketovate Cream Bal Pharma Ltd. India Third Schedule 1451062001T Regesten Cream Bal Pharma Ltd. India Third Schedule 1452082001T DuoVisc Viscoelastic Distributed by Alcon Belgium Third Schedule System Laboratories, Inc. USA Made by Alcon-Couvreur 1453082001T Travatan Ophthalmic Alcon Laboratories, Inc. USA Third Schedule Solution 0.004% 1454082001T Prefest Tablets Ortho Pharmaceutical Puerto Rico Third Schedule (Div. of OMJ Pharms., Inc.) 1455082001 Strepsils Pain Relief Crookes Healthcare England Freely Spray Limited 1456082001 Strepsils Cough Crookes Healthcare England Freely Lozenges Limited 1457082001T Diovan 80 Tablets Novartis Pharma AG Switzerland Third Schedule 1458082001T Diovan 160 Tablets Novartis Pharma AG Switzerland Third Schedule 1459082001T Miflonide 200mcg Manufactured by PCH Int The Third Schedule DAN TRADE NAME AND MANUFACTURER COUNTRY CONDITION FORM OF ORIGIN OF SALE Inhalation Capsules for Novartis Netherlands Pharmaceuticals UK Ltd. Great Britain 1460082001T Miflonide 400mcg Manufactured by PCH Int The Third Schedule Inhalation Capsules for Novartis Netherlands Pharmaceuticals UK Ltd. Great Britain 1461082001T Trizivir Tablets Glaxo Wellcome United Third Schedule Operations Kingdom 1462082001T Celoftal Ophthalmic Alcon-Couvreur Belgium Third Schedule Viscosurgical Device 1463082001 Seven Seas JointCare Seven Seas Health Care England Freely Once-A-Day Pure Cod Ltd. Liver Oil Plus Glucosamine Capsules 1464082001 Seven Seas High Seven Seas Health Care England Freely Potency Glucosamine Ltd. with Chondroitin Active Gel Capsules 1465082001 Seven Seas High Seven Seas Health Care England Freely Potency Effervescent Ltd. Glucosamine with Vitamin C Tablets - Orange Flavour 1466082001 Haliborange Orange Seven Seas Health Care England Freely Flavour Multivitamin Ltd. Liquid 1467082001 Schiff Vitamin A 10,000 Schiff Products USA Freely IU Softgels 1468082001 Schiff Vitamin E 1,000 Schiff Products USA Freely IU Softgels 1469082001 Family Medic Topical Tender Corporation USA Freely Analgesic Solution 1470082001 Family Medic Topical Tender Corporation USA Freely Analgesic Spray 1471082001T Reminyl Film-Coated Manufactured by Janssen- Italy Third Schedule Tablets 4mg Cilag SpA for Janssen Pharmaceutica N.V. Belgium DAN TRADE NAME AND MANUFACTURER COUNTRY CONDITION FORM OF ORIGIN OF SALE 1472082001T Reminyl Film-Coated Manufactured by Janssen- Italy Third Schedule Tablets 8mg Cilag SpA for Janssen Pharmaceutica N.V. Belgium 1473082001T Reminyl Film-Coated Manufactured by Janssen- Italy Third Schedule Tablets 12mg Cilag SpA for Janssen Pharmaceutica N.V. Belgium 1474082001T Reminyl Oral Solution Janssen Pharmaceutica Belgium Third Schedule 4mg/ml N.V. 1475082001T Depakote® ER Abbott Laboratories USA Third Schedule Extended - Release Tablets 500mg 1476082001T Glivec Hard Capsules Novartis Pharma AG Switzerland Third Schedule 100mg 1477082001T Velorin 100 Film- Remedica Ltd Cyprus Third Schedule Coated Tablets 1478082001T Perofen 600 Film- Remedica Ltd Cyprus Third Schedule Coated Tablets 1479082001T Credanil 25/100 Tablets Remedica Ltd Cyprus Third Schedule 1480082001T Petilin 200 Enteric- Remedica Ltd Cyprus Third Schedule Coated Tablets 1481082001T Korandil 10 Tablets Remedica Ltd Cyprus Third Schedule 1482082001T Imuprin 50 Tablets Remedica Ltd Cyprus Third Schedule 1483082001T Cardilor 200 Tablets Remedica Ltd Cyprus Third Schedule 1484082001T Carbachol Injection Bioniche Inc. Canada Third Schedule 0.25mg/mL 1485082001T Cystistat Solution Bioniche Life Sciences Inc. Canada Third Schedule 1486082001 Glucosamine Sulfate & Capsulab Laboratories Inc. Canada Freely Chondroitin Sulfate - For Naka Herbs & 90+ Capsules 900mg Vitamins Ltd. Canada 1487082001 Centrum Performance Whitehall-Robins USA Freely Tablets Healthcare 1488082001T Elequine Tablets 250mg Cilag de Mexico, S.A. de Mexico Third Schedule C.V. 1489082001T Symbicort Turbuhaler AstraZeneca AB Sweden Third Schedule Inhalation Powder 80/4.5 ug/dose DAN TRADE NAME AND MANUFACTURER COUNTRY CONDITION FORM OF ORIGIN OF SALE 1490082001T Symbicort Turbuhaler AstraZeneca AB Sweden Third Schedule Inhalation Powder 160/4.5 ug/dose 1491082001T Nexium Tablets 20mg AstraZeneca AB Sweden Third Schedule 1492082001T Nexium Tablets 40mg AstraZeneca AB Sweden Third Schedule 1493082001T Terbisil Tablets 250mg Gedeon Richter LTD Hungary Third Schedule 1494082001 Beehive Balsam Oral Ayrton Saunders Ltd. England Freely Suspension 1495082001T Batrafen® Gel Aventis Pharma Germany Third Schedule Deutschland GmbH 1496082001 Chlor-O-Phan New GPC Inc. Guyana Freely Expectorant 1497082001T Tramal ® long Film Tecnandina S.A. For Ecuador Third Schedule Coated Tablets 100mg Grunenthal Ecuatoriana C. LTDA. 1498082001 No More Fungus Del Laboratories, Inc. USA Freely Antifungal Liquid 1499082001T Aeroflux Solution Glaxo Wellcome Mexico, Mexico Third Schedule S.A. de C.V. 1500082001T Nootropil I.V. Infusion UCB Pharma S.p.A. Italy Third Schedule Solution 12g/60ml 1501082001T Infanrix Hexa Vaccine SmithKline Beecham Belgium Third Schedule Biologicals s.a. 1502082001 Baby Meltus Cough Seton Healthcare Group England Freely Linctus plc 1503082001 Junior Meltus Seton Healthcare Group England Freely Expectorant plc 1504082001 Adult Meltus Dry Tickly Seton Healthcare Group England Freely Cough Liquid plc 1505082001 Honey & Lemon Meltus Seton Healthcare Group England Freely Expectorant plc 1506082001 Ralgex Heat Spray Seton Healthcare Group England Freely plc 1507082001 Woodward’s Colic Seton Healthcare Group England Freely Drops plc 1508082001 Woodward’s Baby Seton Healthcare Group England Freely Chest Rub plc 1509082001 Junior Meltus Dry Seton Healthcare Group England Freely DAN TRADE NAME AND MANUFACTURER COUNTRY CONDITION FORM OF ORIGIN OF SALE Cough Liquid plc 1510082001 Adult Meltus Seton Healthcare Group England Freely Expectorant plc 1511082001 Bronalin Dry Cough Seton Healthcare Group England Freely Elixir plc 1512082001 Bronalin Junior Linctus Seton Healthcare Group England Freely plc 1513082001 Bronalin Expectorant Seton Healthcare Group England Freely Linctus plc 1514082001T Isoflurane, USP Liquid Halocarbon Laboratories USA Third Schedule For Inhalation 1515082001T Celedol-100 Capsules Ipca Laboratories Ltd. India Third Schedule 1516082001T Celedol-200 Capsules Ipca Laboratories Ltd. India Third Schedule 1517082001T Emnorm-500 Tablets Ipca Laboratories Ltd. India Third Schedule 1518082001T Emnorm-850 Tablets Ipca Laboratories Ltd. India Third Schedule 1519082001 Glucosamine-1000 Plus Pharmavigor Canada Freely F.O.S. Liquid Ampoules 1520082001 Children’s Tylenol Cold McNeil Consumer USA Freely Suspension Liquid – Healthcare Division of Cold Plus Cough McNeil – PPC, Inc. (Cherry Flavor) 1521082001 Schiff Move Free Schiff Products USA Freely Tablets (Change in Name and Form) 1522082001T Viracept Oral Powder F. Hoffmann-La Roche Switzerland Third Schedule 50mg/g (Additional Ltd Source) 1523082001C Rivotril Drops Roche S.p.A. Italy Controlled 2.5mg/ml (Additional Source) 1524082001C Rivotril Drops Produtos Roche Quimicos Brasil Controlled 2.5mg/ml (Additional e Farmaceuticos S.A. Source) 1525082001T Topamax Tablets 25mg Janssen Ortho LLC Puerto Rico Third Schedule (Change of Source) 1526082001T Topamax Tablets Janssen Ortho LLC Puerto Rico Third Schedule 100mg (Change of Source) DAN TRADE NAME AND MANUFACTURER COUNTRY CONDITION FORM OF ORIGIN OF SALE 1527082001T Adalat OROS Tablets Bayer AG Germany El Salvador Third Schedule 30mg (Change in Name Packaged by Bayer de El of Manufacturer and Salvador S.A. Change of Source) 1528082001T Canesten Pump Spray Corporacion Bonima, S.A. El Salvador Third Schedule Solution (Change in de C.V. under control of Name of Manufacturer) Bayer, S.A. 1529082001T Quamatel Film-Coated Gedeon Richter LTD Hungary Third Schedule Tablets 20mg (Change of Artwork Design) 1530082001T Quamatel Film-Coated Gedeon Richter LTD Hungary Third Schedule Tablets 40mg (Change of Artwork Design) 1531082001T Nasacort AQ Nasal Fisons Limited for Aventis England Third Schedule Spray Suspension Pharma, S.A. (Additional Source) 1532082001T Zyrtec Film-Coated UCB Farchim SA Switzerland Third Schedule Tablets 10mg (Additional Source) 1533082001T Engerix-B Suspension SmithKline Beecham Belgium Third Schedule for Injection - Adult Biologicals s.a. Dose (Change of Formula) 1534082001 Hexi-Cream (Change of Genethics Pharmaceuticals Trinidad & Freely Name) Ltd. Tobago 1535082001 Nut-Med Instant Pain Noelville Ltd. Grenada Freely Relieving Spray (Pharmaceutical Div.) 1536082001 Ginseng-2000 Plus Pharmavigor Canada Freely F.O.S. Liquid Ampoules 1537082001 Ginkgo Biloba-120 Plus Pharmavigor Canada Freely F.O.S. Liquid Ampoules 1538082001 Echinacea-240 Plus Pharmavigor Canada Freely F.O.S. Liquid Ampoules 1539082001T Dia-Beat Capsules 400 Health 2000 Canada Third Schedule mg 1540082001T Hetorine Liquid Holistic
Load more

Recommended publications
  • SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI Trading As ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP
    Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI trading as ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP. COTTON GREEN RLY. STN. MUMBAI-400033. MANUFACTURE & MERCHANT INDIAN NATIONAL Used Since :31/01/2001 MUMBAI MEDICINAL PREPARATIONS. 537 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SEPTIGARD 1741718 08/10/2008 INDERJIT SINGH trading as ;INDERJIT SINGH B-104 , SWASTHYA SINGH , NEW DELHI -92 MERCHANTS & MANUFACTUERERS Address for service in India/Agents address: MAHTTA & CO. 43 - B/3, MAHTTA HOUSE,UDHAM SINGH NAGAR, LUDHIANA - 141 001, (PUNJAB). Proposed to be Used DELHI MEDICINAL & PHARMACEUTICAL PREPARATIONS. 538 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 FAIR & BEAUTY 1803779 08/04/2009 GALPHA LABORATORIES LIMITED 221, Kanakia Zillion, E Wing Bandra Kurla Complex Annex LBS Marg & CST Road Junction Kurla West MUMBAI 400070 MANUFACTURERS AND MERCHANTS INDIAN NATIONAL Used Since :15/11/2007 MUMBAI PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES 539 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 O-BAMA 1815900 08/05/2009 KREMOINT PHARMA PVT. LTD. 151/5, SHRI KRISHNA DARSHAN, GARODIA NAGAR, GHATKOPAR (E), BOMBAY-400 077. MANUFACTURERS AND MERCHANTS. A CORPORATE ENTITY INCORPORATED IN INDIA UNDER THE COMPANIES ACT 1956. Address for service in India/Attorney address: KRISLAW CONSULTANTS BUILDING NO.4, C/104, SHANKESHWAR PALMS, BEHIND MODEL SCHOOL, KUMBHARKHANPADA, SUBHASH ROAD, DOMBIVILI(W) 421202 Used Since :02/05/2009 MUMBAI PHARMACETICAL AND MEDICINAL PREPARATIONS. 540 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 AYUSHAKTI D-VYRO 1815928 08/05/2009 SMITA NARAM BUNGALOW NO.31, NEXT TO M.
    [Show full text]
  • Replacements in Indices
    Date: February 21, 2018 PRESS RELEASE Replacements in Indices The Index Maintenance Sub-Committee (IMSC) has decided to make the following replacement of stocks in various indices as part of its periodic review. These changes shall become effective from April 02, 2018 (close of March 28, 2018). 1) NIFTY 50 The following companies are being excluded: Sr. No. Company Name Symbol 1 Ambuja Cements Ltd. AMBUJACEM 2 Aurobindo Pharma Ltd. AUROPHARMA 3 Bosch Ltd. BOSCHLTD The following companies are being included: Sr. No. Company Name Symbol 1 Bajaj Finserv Ltd. BAJAJFINSV 2 Grasim Industries Ltd. GRASIM 3 Titan Company Ltd. TITAN The above replacements will also be applicable to NIFTY50 Equal Weight Index. 2) NIFTY Next 50 The following companies are being excluded: Sr. No. Company Name Symbol 1 Bajaj Finserv Ltd. BAJAJFINSV 2 GlaxoSmithkline Consumer Healthcare Ltd. GSKCONS 3 Glaxosmithkline Pharmaceuticals Ltd. GLAXO 4 Glenmark Pharmaceuticals Ltd. GLENMARK 5 Tata Power Co. Ltd. TATAPOWER 6 Titan Company Ltd. TITAN 7 Torrent Pharmaceuticals Ltd. TORNTPHARM The following companies are being included: Sr. No. Company Name Symbol 1 Aditya Birla Capital Ltd. ABCAPITAL Sr. No. Company Name Symbol 2 Ambuja Cements Ltd. AMBUJACEM 3 Aurobindo Pharma Ltd. AUROPHARMA 4 Bosch Ltd. BOSCHLTD 5 General Insurance Corporation of India GICRE 6 L&T Finance Holdings Ltd. L&TFH 7 SBI Life Insurance Company Ltd. SBILIFE 3) NIFTY 500 The following companies are being excluded: Sr. No. Company Name Symbol 1 Adani Enterprises Ltd. ADANIENT 2 Ahluwalia Contracts (India) Ltd. AHLUCONT 3 Apar Industries Ltd. APARINDS 4 AstraZenca Pharma India Ltd. ASTRAZEN 5 Corporation Bank CORPBANK 6 Dalmia Bharat Ltd.
    [Show full text]
  • 50 KW Offer Solar Copy 2
    21st Century Enviro Engineers Pvt.Ltd. Plot No. 120(10 Marla), COMPANY Industrial Area Phase II Chandigarh - 160002, India PROFILE www.21stcenturyenviro.com INTRODUCTION 21st CENTURY ENVIRO ENGINEERS PVT. LTD. is a Company dealing in the field of Environmental Engineering related activities. We are Registered Environmental Consultants of Pollution Control Board to Supply ETP’s, STP’s, APCD’s, Incinerators, Water Treatment Plants, Reverse Osmosis, Evaporators, Solid Waste Management and Rain Water Harvesting and to carry out EIA Studies . The Directors of the company are young Technocrats having versatile experience in this field. We have a back up of highly qualified and experienced technical team having versatile experience in Designing, Erection, Commissioning and Operation of different types of Effluent Treatment Plants. Our Managing Director himself is a Chemical Engineer with almost 25 Years Experience in this line and Technical Director is PhD. in Environmental Science with almost 30 Years working experience on various types of effluent treatment Technologies. Our team comprises of almost 150 people from different backgrounds e.g. Chemical, Environmental, Mechanical, Instrumentation, Civil, Accounts, Purchase, Marketing etc. We have our Marketing/ Design Office in Chandigarh and regional offices in Dhaka, Mumbai, New Delhi, Sikkim etc. and have our own testing Laboratory for Effluent/Water Testing and to study treatability of effluent on pilot scale. We have our own full-fledged manufacturing unit of Pollution Control Equipments in Village Kunjhal Baddi (HP). We also undertake annual operation and maintenance contracts and liasining services for the systems supplied by us. We are also Registered with CREST (Chandigarh Renewable Energy & Technology Promotion Society) and SECI (Solar Energy Corporation of India) for supplying Online/Offline Solar systems in Chandigarh, Himachal Pradesh, Uttarakhand, J&K, Punjab, Haryana, Delhi, Bihar etc.
    [Show full text]
  • Index Stock Update >> Marico Stock Update >> Gabriel India Stock Update >> PTC India Stock
    Visit us at www.sharekhan.com November 04, 2015 Index Stock Update >> Marico Stock Update >> Gabriel India Stock Update >> PTC India Stock Update >> Ipca Laboratories Stock Update >> Skipper Viewpoint >> Lloyd Electric & Engineering For Private Circulation only REGISTRATION DETAILS Regd Add: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos. BSE - INB/INF011073351 ; BSE- CD ; NSE - INB/ INF231073330 ; CD-INE231073330 ; MSEI - INB/INF261073333 ; CD-INE261073330 ; DP - NSDL-IN-DP-NSDL-233-2003 ; CDSL-IN-DP-CDSL-271-2004 ; PMS- INP000000662 ; Mutual Fund-ARN 20669 ; Commodity trading through Sharekhan Commodities Pvt. Ltd.: MCX-10080 ; (MCX/TCM/CORP/0425) ; NCDEX- 00132 ; (NCDEX/TCM/CORP/0142) ; NCDEX SPOT-NCDEXSPOT/116/CO/11/20626 ; For any complaints email at [email protected] ; Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and Do’s & Don’ts by MCX & NCDEX and the T & C on www.sharekhan.com before investing. investor’s eye stock update Marico Reco: Buy Stock Update Enhanced focus to improve volume growth; maintain Buy CMP: Rs399 Company details Key points Price target: Rs460 Mixed operating performance: During Q2FY2016, Marico’s revenue grew by 4% to Rs1,485.4 crore, entirely driven by a 4% volume growth (domestic business’ volume Market cap: Rs25,735 cr growth stood at 5.5%). The gross profit margin (GPM) improved by almost 500BPS to 52 week high/low: Rs466/299 49.3% on the back of ~30% decline in the copra prices and 33% decline in the prices of liquid paraffin.
    [Show full text]
  • Ajanta Pharma Limited
    AJANTA PHARMA LIMITED CIN : L24230MH1979PLC022059 Registered & Corporate Office: ‘Ajanta House’, 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India Tel.: +91 22 6606 1000, Fax: +91 22 6606 1200 | E-mail: [email protected] | Website: www.ajantapharma.com POST BUYBACK PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF EQUITY SHARES OF AJANTA PHARMA LIMITED This public announcement (the “Post Buyback Public Announcement”) is being made pursuant to the provisions of Regulation 24(vi) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, for the time being in force including any statutory modifications and amendments from time to time (the “Buyback Regulations”). This Post Buyback Public Announcement should be read in conjunction with the Public Announcement dated November 4, 2020 which was published on November 5, 2020 (the “Public Announcement”) and the letter of offer dated November 25, 2020 (the “Letter of Offer”) issued in connection with the Buyback. The terms used but not defined in this Post Buyback Public Announcement shall have the same meanings as assigned in the Public Announcement and the Letter of Offer. 1. THE BUYBACK 1.1 Ajanta Pharma Limited (the “Company”) had announced the Buyback of not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) fully paid-up equity shares of face value of ₹2 each (“Equity Shares”) from all the existing shareholders / beneficial owners of Equity Shares as on the record date (i.e. Friday, November 13, 2020), on a proportionate basis, through the “Tender Offer” process at a price of ₹1,850/- (Rupees One Thousand Eight Hundred and Fifty Only) per Equity Share payable in cash for an aggregate consideration not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding the Transaction Costs (“Buyback Offer Size”).
    [Show full text]
  • Inner 25 India Pharma & Healthcare Fund
    Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata India Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th June 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 55184.24 97.88 Glenmark Pharmaceuticals Ltd. 167000 1089.76 1.93 INVESTMENT OBJECTIVE Healthcare Services Sanofi India Ltd. 13000 997.39 1.77 The investment objective of the scheme is to seek long Apollo Hospitals Enterprise Ltd. 70500 2551.99 4.53 Gland Pharma Ltd. 19662 673.29 1.19 term capital appreciation by investing atleast 80% of its Fortis Healthcare Ltd. 795000 1935.03 3.43 Laurus Labs Ltd. 90000 619.79 1.10 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Syngene International Ltd. 265000 1545.75 2.74 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Narayana Hrudayalaya Ltd. 301420 1483.74 2.63 Other Equities^ 1186.14 2.10 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd.
    [Show full text]
  • MF 35 Fund One Pager
    BR“BuyS RightT : BSit TightR” ST BRSnowT Bin fourRS differentTBRS colorsTBRS BRSTBRSTBRSTBR Motilal Oswal MOSt Focused Invests in enduring B25 RFund STBRSTBwRealth creaStors T Motilal Oswal MOSt Focused Invests in emerging BMidcapR 30 Fund TBRwealth creators T BRSTBSRSTBRSTBSRS Motilal Oswal MOSt Focused Invests in emerging and BMulticapRS 35 FundT BRSTBRenduringST wealthB creatorRs Lock in fund that invests Motilal Oswal MOSt Focused in wealth creators BLongR Term SFund TBRSTBplusR Saves TSax T BR TBR T BRSTBSRSTBRSTBSRS Focused Low Churn QGLP No load BRSTBPortfolioRSTBPortfolioRSTStocksBR BRSInvesTt nowB to addR colorSs Tto yourB porRolioST BRSCall:T 1800-200-6626B | SMS:R FOCUSS to 575753T BRSTBRS Website: www.motilaloswalmf.com Our Investment Philosophy The recommended way to create Wealth from equity- 'Buy Right : Sit Tight' At Molal Oswal Asset Management Company (MOAMC), our investment philosophy and invesng style is centered on 'Buy Right: Sit Tight‘ principal. ‘Buy Right' means buying quality companies at a reasonable price and 'Sit Tight' means staying invested in them for a longer me to realise the full growth potenal of the stocks. Buy Right Stock Characteristics Sit Tight Approach QGLP ‘Q’uality denotes quality of the business and Buy and Hold: We are strictly buy and hold management investors and believe that picking the right ‘G’rowth denotes growth in earnings and business needs skill and holding onto these sustained RoE businesses to enable our investors to benefit from the entire growth cycle needs even more ‘L’ongevity denotes longevity of the skill. competitive advantage or economic moat of the business Focus: Our portfolios are high conviction portfolios with 20 to 25 stocks being our ideal ‘P’rice denotes our approach of buying a good n u m b e r.
    [Show full text]
  • Ipca Laboratories (IPCLAB)
    Ipca Laboratories (IPCLAB) CMP: | 2040 Target: | 2290 (12%) Target Period: 12 months HOLD May 31, 2021 Upbeat guidance, execution remains key Q4 revenues remained subdued growing just 3.8% YoY to | 1115 crore. Strong YoY growth of 19.7% in export formulations to | 338 crore was partly Particulars offset by API sales decline of 5.5% YoY to | 260 crore. Domestic Particular Amount formulations remained flat at | 434 crore vs. | 431 crore in Q4FY20. EBITDA Market Capitalisation | 25873 crore margins improved 484 bps YoY to 20.5% due to better gross margins and Debt (FY21) | 267 crore lower other expenditure. EBITDA grew 35.8% YoY to | 229 crore. PAT grew Cash (FY21) | 365 crore 87.5% YoY to | 161 crore (I-direct estimate: | 204 crore). Delta vis-à-vis EV | 25775 crore EBITDA was due to higher other income, lower depreciation and tax rate. 52 week H/L (|) 2456/1467 Equity capital | 25.4 crore Update Result Export formulations main catalyst for growth Face value | 2 Price performance Growth in export formulations (29% of FY21 revenues) was on the back of growth in both international generics and international branded 2500 14000 formulations. The international anti-malarial institutional business has also 12000 2000 contributed substantially to overall exports growth. US traction will take 10000 longer than earlier estimated due to USFDA import alerts for the Ratlam 1500 8000 facility that is the only API source for Silvassa and Pithampur formulations 1000 6000 plants along with Silvassa and Pithampur (Indore) plants that are specifically 4000 500 earmarked for the US business, besides third party sales.
    [Show full text]
  • CARE Ratings Ltd
    CARE/HO/RL/2020-21/2749 Mr. Arvind Agrawal Chief Financial Officer Ajanta Pharma Limited Ajanta House, Charkop, Kandivali (W), Mumbai-400067 October 1, 2020 Confidential Dear Sir, Credit rating for bank facilities On the basis of recent developments including operational and financial performance of your company for FY20 (audited) and Q1FY21 (provisional), our Rating Committee has reviewed the following ratings: Facilities Amount Rating1 Rating (Rs. crore) Action Long-term/Short-term Bank 55.00 CARE AA; Stable/CARE A1+ Facilities (reduced from 87.50) (Double A; Outlook: Stable/A Reaffirmed One Plus) Total 55.00 (Rs. Fifty Five crore only) 2. Refer Annexure 1 for details of rated facilities. 3. The rationale for the rating will be communicated to you separately. A write-up (press release) on the above rating is proposed to be issued to the press shortly, a draft of which is enclosed for your perusal as Annexure-2. We request you to peruse the annexed document and offer your comments if any. We are doing this as a matter of courtesy to our clients and with a view to ensure that no factual inaccuracies have inadvertently crept in. Kindly revert as early as possible. In any case, if we do not hear from you by October 5, 2020 we will proceed on the basis that you have no any comments to offer. 4. CARE reserves the right to undertake a surveillance/review of the rating from time to time, based on circumstances warranting such review, subject to at least one such review/surveillance every year. 5.
    [Show full text]
  • Pharma Sector Report -Sept’20
    Mutual Fund: Pharma Sector Report -Sept’20 Private & confidential. Only for limited circulation. Contact us: [email protected] Executive Summary: Since the outbreak of the Coronavirus crisis, the pharma sector stepped into the spotlight. Long overdue investments have been flowing towards the sector and even pharma funds in the mutual fund industry have begun to outperform. Nevertheless, there is still a clear need for government spending in this sector. Compared to the US, which has the highest per capita spending on healthcare at $5000, India spends merely ~ $50 per capita. The current situation presents the Indian government with a perfect opportunity to increase its expenditure in this sector, to facilitate its growth and fast-track its progress. Few points about the Pharma Funds: The market capitalization of the entire pharma & healthcare industry is ~ Rs. 10 lac crs, whereas the total size of pharma funds in the mutual fund is ~Rs. 10k crs, translating to ~ 1% of the entire sector in value terms. (This excludes the pharma holdings in other categories). There are 43 pharma & healthcare companies that form part of the Top 500 companies. Out of these, pharma funds have an exposure to 36 companies. There are 11 companies in the Top 100; 11 in the Midcap space (101-250) and 14 Smallcaps (251-500). The 7 companies that do not form part of the pharma funds’ portfolios are Caplin Point Lab, Glenmark Pharma, Granules India, Piramal Enterprises, Poly Medicure, Suven Pharma and Wockhardt Ltd. Cipla Ltd., Divis Laboratories Ltd. and Dr. Reddy’s Laboratories Ltd. are the only stocks that form part of every pharma fund.
    [Show full text]
  • List of 3Rd Party Manufacturer of Pre-Qualified/Registered Firms with PPT Hospital
    List of 3rd party Manufacturer of Pre-qualified/Registered Firms with PPT Hospital SL. Name of the Parent Firm Name of the 3rd party manufacturer NO A B C 1 M/s AKUMENTIS HEALTHCARE LTD. (i) M/S Unimark Healthcare Ltd (ii) M/S Applied Communication & Controls (iii) Maxcure Nutravedics Ltd (iv) Akums Drugs & Pharmaceuticals Ltd 2 M/s ALCON LABORATORIES(INDIA)PVT.LTD (i) M/S Wintac Limited 3 M/s ABBOTT HEALTHCARE PVT. LTD. (i) Akums Drugs & Pharmaceuticals Ltd (ii) Medibios Laboratories Pvt. Ltd. (iii) Tristar Formulations Pvt. Ltd. (iv) Hetero Labs Ltd (v) M/S Aqua Vitoe Laboratories 4 M/s ABBOTT INDIA LIMITED. (i) Acme Formulation Pvt Ltd (ii) Revenbhel Healthcare Pvt. Ltd. 5 M/s CENTAUR PHARMACEUTICALS PVT. LTD. (i) M/S Pure & Cure Healthcare Pvt. Ltd. (ii) M/S The Madras Pharmaceuticals (iii) M/S Akums Drugs & Pharmaceuticals Limited 6 M/S CIPLA LIMITED (i) Akums Drugs & Pharmaceuticals Ltd (ii) BDR Pharmaceuticals International Pvt. Ltd. (iii) M/S Medispray Laboratories Pvt. Ltd. (iv) M/S Golden Cross Pharma Pvt. Ltd. (v) M/S Tirupati Medicare Limited (vi) M/S Mepromax Lifesciences PVT Ltd. (vii) M/S Virchow Biotech Private Limited (viii) Hetero Labs Ltd (ix) Pegasus Farmaco Iindia Pvt. Ltd. (x) Meditab Specialities Pvt. Ltd. 7 M/s DR. REDDYS LABORATORIES LTD (i) Bdr Pharmaceuticals Ltd (ii) Naprod Lifesciences Pvt. Ltd (iii) Hetero Labs Ltd (iv) Natco Pharma Ltd (v) Amgen Manufacturing Limited 8 M/s FOURRTS (INDIA) LABORATORIES PVT. (i) M/S Swiss Garnier Biotech (ii) M/S Sun Glow Pharmaceuticals Private Limited 9 M/s GLOBUS REMEDIES (i) Park Pharmaceuticals (ii) Baxil Pharma Pvt.
    [Show full text]
  • PUBLIC ANNOUNCEMENT for the ATTENTION of EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS of As Partner of Ganga Exports, Where the Partner’S Share Being 37.5%
    ii. Shareholding of directors of the Promoters and Promoter Group entity (i.e. Gabs Investment Private Limited ii. the amount of permissible capital payment (including premium) as stated in Annexure A for the proposed (“GIPL”)) in the Company: buy-back of equity shares has been properly determined considering the audited standalone financial statements and audited consolidated financial statements in accordance with Section 68(2) of the Act; and Sr. Designation No. of Equity Shares held Percentage (%) of issued Name iii. the Board of Directors of the Company in their meeting dated 3 November 2020, have formed the opinion No. in GIPL in the Company Equity Share capital as specified in clause (x) of Schedule I to the SEBI Buy-back Regulations on reasonable grounds and 1. Yogesh Agrawal Director 1,35,36,523(1) 15.51 that the Company will not, having regard to its state of affairs, be rendered insolvent within a period AJANTA PHARMA LIMITED 2. Rajesh Agrawal Director 1,35,36,522(2) 15.51 of one year from that date. CIN : L24230MH1979PLC022059 3. Ravi Agrawal Director 1,33,32,906(3) 15.28 Auditors’ Responsibility (Continued) Registered & Corporate Office: ‘Ajanta House’, 98 Govt Industrial Area, Charkop, 4. Aayush Agrawal Director 1,25,60,389(4) 14.39 5. The audited standalone financial statements and audited consolidated financial statements referred to in Kandivli (West), Mumbai - 400 067, Maharashtra, India Total 5,29,66,340 60.69 paragraph 5 above, which we have considered for the purpose of this report, have been audited by us, on Tel.: +91 22 6606 1000, Fax: +91 22 6606 1200 | E-mail: [email protected] which we have issued an unmodified audit opinion vide our reports dated 20 May 2020.
    [Show full text]